0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$243.00
This product is available by prescription only
This product does not require a prescription
Out Of Stock
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
This synthetic research peptide formulation provides laboratories with a standardized dual-agonist compound for comprehensive experimental studies. The 50mg format supports extended research applications and multiple experimental protocols. Each batch undergoes rigorous purity verification to ensure consistency across research series. High-purity formulation meets research-grade standards for dual-receptor peptide investigations. Secure packaging protects compound integrity during storage and transport. Discreet shipment ensures confidential delivery to research facilities and institutional laboratories.
Researchers investigate Tirzepatide within controlled laboratory environments to examine dual-receptor peptide mechanisms. Experimental receptor-binding models utilize this compound to study dual-agonist characteristics in vitro. Controlled laboratory peptide stability studies assess compound properties under standardized experimental conditions. Scientists explore structural attributes and dual-receptor interaction patterns in research settings. Laboratory personnel examine peptide behavior in experimental models designed for receptor-binding research. These investigations occur exclusively in controlled research environments without clinical applications.
Tirzepatide is investigated in research environments to understand dual-receptor interaction mechanisms. This compound is studied within controlled laboratory models examining peptide-receptor properties. Researchers explore this peptide for experimental peptide research applications in academic and institutional settings. Laboratory studies examine the compound’s dual-agonist characteristics under standardized protocols. Scientists investigate structural properties relevant to receptor-binding research methodologies. All research applications remain confined to laboratory environments and experimental frameworks.
Store Tirzepatide in cool, dry conditions protected from light exposure. Storage temperature should remain consistent to maintain compound stability. Keep the product sealed until ready for laboratory use. Laboratory handling should occur only by qualified research personnel trained in peptide research protocols. Avoid exposure to moisture, heat, and direct sunlight during storage. Use appropriate laboratory equipment when handling this research compound. Reconstitution should follow standard laboratory peptide preparation procedures using sterile techniques. Maintain proper documentation of handling and storage conditions for research records. Dispose of unused material according to institutional laboratory waste protocols.
Each batch undergoes comprehensive purity verification procedures to confirm research-grade quality. Third-party testing validates compound purity at 99%+ by HPLC analysis. Batch-to-batch consistency ensures reliable results across research protocols. Certificate of Analysis accompanies each order documenting purity verification results. Internal quality assurance standards maintain strict compound specifications. Testing procedures verify molecular weight, purity percentage, and compound identity. Research-grade supply positioning ensures suitability for controlled laboratory investigations. Quality control documentation supports institutional research compliance requirements.
Tirzepatide is a synthetic dual-agonist peptide compound produced for research applications. A dual-agonist peptide is a molecular structure designed to interact with two different receptor types in experimental models. Receptors are proteins that receive molecular signals in laboratory test systems. This peptide’s structure allows it to bind with multiple receptor types simultaneously in experimental settings. This synthetic peptide origin ensures batch-to-batch consistency for research protocols. The compound consists of a defined amino acid sequence with specific modifications for dual-receptor studies. Researchers examine this peptide’s properties within controlled laboratory conditions without therapeutic context.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic dual-peptide formulation combining amylin analog and GLP-1 receptor agonist for dual-mechanism pathway studies and combination peptide research in controlled laboratory environments.
Research-grade selective synthetic pentapeptide formulated for experimental peptide interaction research in controlled laboratory settings.
Research-grade synthetic peptide formulated in mid-range 10mg quantity for cellular migration studies and peptide actin-binding research in controlled laboratory environments.
Research-grade synthetic peptide analog formulated for experimental metabolic pathway research in controlled laboratory environments.
A synthetic aromatic-cationic tetrapeptide studied for selective inner mitochondrial membrane localization, cardiolipin binding dynamics, and oxidative phosphorylation pathway marker activity in controlled in-vitro and preclinical models.
